Genomic Health, Inc. (NASDAQ:GHDX) insider Kimberly J. Popovits sold 10,000 shares of the firm’s stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $34.99, for a total value of $349,900.00. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Kimberly J. Popovits also recently made the following trade(s):

  • On Thursday, December 14th, Kimberly J. Popovits sold 20,000 shares of Genomic Health stock. The shares were sold at an average price of $31.50, for a total value of $630,000.00.

Genomic Health, Inc. (NASDAQ:GHDX) opened at $33.88 on Friday. The stock has a market capitalization of $1,178.52, a PE ratio of -282.33 and a beta of 0.66. Genomic Health, Inc. has a 52-week low of $26.37 and a 52-week high of $37.50.

Genomic Health (NASDAQ:GHDX) last posted its quarterly earnings results on Wednesday, November 8th. The medical research company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.01) by $0.04. Genomic Health had a negative return on equity of 1.79% and a negative net margin of 1.30%. analysts predict that Genomic Health, Inc. will post -0.08 earnings per share for the current year.

Several institutional investors and hedge funds have recently bought and sold shares of GHDX. Cubist Systematic Strategies LLC purchased a new position in shares of Genomic Health in the 3rd quarter worth about $138,000. SG Americas Securities LLC increased its holdings in Genomic Health by 37.8% in the 2nd quarter. SG Americas Securities LLC now owns 6,122 shares of the medical research company’s stock worth $199,000 after buying an additional 1,679 shares in the last quarter. Legal & General Group Plc increased its holdings in Genomic Health by 11.4% in the 2nd quarter. Legal & General Group Plc now owns 6,932 shares of the medical research company’s stock worth $226,000 after buying an additional 710 shares in the last quarter. Jane Street Group LLC bought a new stake in Genomic Health in the 3rd quarter worth about $227,000. Finally, Parametric Portfolio Associates LLC increased its holdings in Genomic Health by 5.8% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 8,051 shares of the medical research company’s stock worth $262,000 after buying an additional 441 shares in the last quarter. 89.83% of the stock is owned by hedge funds and other institutional investors.

Several equities analysts have commented on the company. Canaccord Genuity reissued a “buy” rating and set a $42.00 price objective on shares of Genomic Health in a research report on Tuesday, January 16th. Zacks Investment Research raised Genomic Health from a “sell” rating to a “hold” rating in a research report on Friday, October 13th. JPMorgan Chase & Co. lowered Genomic Health from a “neutral” rating to an “underweight” rating and set a $25.00 price target for the company. in a research report on Wednesday, December 13th. ValuEngine lowered Genomic Health from a “hold” rating to a “sell” rating in a research report on Thursday, November 9th. Finally, BidaskClub raised Genomic Health from a “sell” rating to a “hold” rating in a research report on Tuesday, December 19th. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and one has given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $32.33.

TRADEMARK VIOLATION NOTICE: “Genomic Health, Inc. (GHDX) Insider Kimberly J. Popovits Sells 10,000 Shares” was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The correct version of this report can be read at https://www.watchlistnews.com/genomic-health-inc-ghdx-insider-kimberly-j-popovits-sells-10000-shares/1816866.html.

About Genomic Health

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Insider Buying and Selling by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.